...
【24h】

PET-Based Primary Tumor Volumetric Parameters and Survival of Patients With Non-Small Cell Lung Carcinoma.

机译:非小细胞肺癌患者基于PET的原发性肿瘤体积参数和生存率。

获取原文
获取原文并翻译 | 示例
           

摘要

The purpose of the study was to assess metabolic tumor volume and total glycolytic activity of the primary tumor as prognostic parameters for outcome in patients with non-small cell lung carcinoma (NSCLC).Thirty-nine patients who had undergone a baseline staging PET/CT examination at our institution for the diagnosis of NSCLC were retrospectively identified. The maximum standardized uptake value (SUV(max)), metabolic tumor volume, and total glycolytic activity were segmented from PET using the gradient method; 12-month survival and overall survival at the end of follow-up were used as outcome measures. Multivariate logistic regression, receiver operating characteristic curve analysis, and Kaplan-Meier curves for survival analysis were generated and compared using the Mantel-Cox log-rank test.The mean gradient-based metabolic tumor volume and gradient-based total glycolytic activity were significantly greater in the patients who died (93.3 mL and 597.5 g) than in those who survived (19.3 mL and 193.9 g, respectively) (p < 0.003 and p < 0.031). There was no statistically significant difference in the mean SUV(max) between the patients who survived (12.7) at 12 months and those who had died (13.1) (p = 0.85). On multivariate analysis, gradient-based metabolic tumor volume was the only variable associated with 12-month mortality when adjusted for all other factors.(.) The area under the curve (AUC) for gradient-based metabolic tumor volume was 0.77 (p < 0.006). A significant difference in the time to survival was observed between high and low gradient-based metabolic tumor volume (log-rank p < 0.05) cohorts using the median gradient-based metabolic tumor volume (9.7 mL) as the cut point.PET-based volumetric imaging parameters are potential prognostic markers of outcome in patients with NSCLC.
机译:这项研究的目的是评估非小细胞肺癌(NSCLC)患者预后的代谢肿瘤体积和原发肿瘤的总糖酵解活性作为预后的参数.39例接受了基线分期PET / CT的患者回顾性地确定了我们机构对NSCLC的诊断检查。用梯度法从PET中分离出最大标准摄取值(SUV(max)),代谢肿瘤体积和总糖酵解活性。随访结束时的12个月生存期和总体生存期用作结果指标。使用Mantel-Cox对数秩检验,生成并比较了多元logistic回归,受试者工作特征曲线分析和用于生存分析的Kaplan-Meier曲线,基于梯度的平均代谢肿瘤体积和基于梯度的总糖酵解活性明显更高死亡的患者(93.3 mL和597.5 g)比存活的患者(分别为19.3 mL和193.9 g)(p <0.003和p <0.031)。在12个月存活的患者(12.7)与死亡的患者(13.1)之间的平均SUV(max)差异无统计学意义(p = 0.85)。在多变量分析中,如果对所有其他因素进行校正,则基于梯度的代谢肿瘤体积是与12个月死亡率相关的唯一变量。(。)基于梯度的代谢肿瘤体积的曲线下面积(AUC)为0.77(p < 0.006)。以中值梯度为基础的代谢肿瘤体积(9.7 mL)为切入点,高梯度和低梯度代谢肿瘤体积(log-rank p <0.05)队列之间的生存时间存在显着差异。体积成像参数是NSCLC患者预后的潜在标志。

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号